North Dakota State Investment Board Takes Position in Zoetis Inc. $ZTS

North Dakota State Investment Board acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 15,307 shares of the company’s stock, valued at approximately $1,926,000.

Several other hedge funds have also recently made changes to their positions in ZTS. Brighton Jones LLC raised its holdings in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after purchasing an additional 657 shares during the last quarter. Intech Investment Management LLC raised its holdings in shares of Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after purchasing an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after purchasing an additional 1,422 shares during the last quarter. Finally, Glenview Trust co raised its holdings in shares of Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock valued at $745,000 after purchasing an additional 506 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ZTS. JPMorgan Chase & Co. decreased their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday, May 8th. UBS Group reduced their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Piper Sandler reaffirmed a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Finally, Bank of America upped their target price on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $134.75.

Insider Activity at Zoetis

In related news, Director Paul Bisaro bought 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Frank A. Damelio bought 6,650 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This represents a 44.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders purchased 11,650 shares of company stock valued at $886,384. Corporate insiders own 0.22% of the company’s stock.

Zoetis Stock Performance

ZTS opened at $77.78 on Tuesday. The firm has a market cap of $32.61 billion, a P/E ratio of 12.90, a PEG ratio of 1.21 and a beta of 0.87. Zoetis Inc. has a 1-year low of $72.38 and a 1-year high of $172.23. The company has a 50 day simple moving average of $111.39 and a two-hundred day simple moving average of $120.28. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities analysts forecast that Zoetis Inc. will post 6.91 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.